Versican expression is an adverse prognostic factor in MLL-rearranged infant acute lymphoblastic leukaemia

Emma M.C. Driessen; Sandra S.Mimoso Pinhanços; Pauline Schneider; Paola De Lorenzo; Maria G. Valsecchi; Rob Pieters; Ronald W. Stam

doi:10.1016/j.ejca.2015.12.031

Versican expression is an adverse prognostic factor in MLL-rearranged infant acute lymphoblastic leukaemia

Emma M.C. Driessen, Sandra S.Mimoso Pinhanços, Pauline Schneider, Paola De Lorenzo, Maria G. Valsecchi, Rob Pieters, Ronald W. Stam

Group Pieters

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

6 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	87-90
Aantal pagina's	4
Tijdschrift	European Journal of Cancer
Volume	57
DOI's	https://doi.org/10.1016/j.ejca.2015.12.031
Status	Gepubliceerd - 1 apr. 2016

Toegang tot document

10.1016/j.ejca.2015.12.031

Citeer dit

@article{75a2c2a3d8c44ab1979e38c75daadb14,

title = "Versican expression is an adverse prognostic factor in MLL-rearranged infant acute lymphoblastic leukaemia",

author = "Driessen, {Emma M.C.} and Pinhan{\c c}os, {Sandra S.Mimoso} and Pauline Schneider and {De Lorenzo}, Paola and Valsecchi, {Maria G.} and Rob Pieters and Stam, {Ronald W.}",

note = "Funding Information: The authors thank the members and participating institutes of the INTERFANT-99 study for generously providing leukaemic samples. Members of the INTERFANT-99 study are as follows: M. Campbell (Programa Infantil Nacional de Drogas Atineoplasicas [PINDA]), M. Felice (Argentina), A. Ferster (Children's Leukaemia Group [CLCG]), I. Hann and A. Vora (UK Children's Cancer Study Group [UKCCSG]), L. Hovi (Nordic Society of Paediatric Haematology and Oncology [NOPHO]), G. Janka-Schaub (Cooperative Study Group for Treatment of ALL [COALL]), C.K. Li (Hong Kong), G. Mann (Berlin-Frankfurt-Munster Group-Austria [BFM-A]), T. LeBlanc (French ALL Group [FRALLE]), R. Pieters (Dutch Childhood Oncology Group [DCOG]), G. de Rossi and A. Biondi (Associazione Italiana Ematologia Oncologia Pediatrica [AIEOP]), J. Rubnitz (St Jude Children's Research Hospital [SJCRH]), M. Schrappe (Berlin–Frankfurt–Munster Group Germany [BFM-G]), L. Silverman (Dana-Farber Cancer Institute [DFCI]), J. Stary (Czech Paediatric Haematology [CPH]), R. Suppiah (Australian and New Zealand Children's Haematology/Oncology Group [ANZCHOG]), T. Szczepanski (Polish Paediatric Leukaemia and Lymphoma Study Group [PPLLSG]), and M. Valsecchi and P. de Lorenzo (Trial Operating Center [CORS]). Research support: this study was financially supported by research funding from KIKA (Kinderen Kankervrij) . Furthermore, RWS was financially supported by the Dutch Cancer Society (KWF Kankerbestrijding) .",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.ejca.2015.12.031",

language = "English",

volume = "57",

pages = "87--90",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Versican expression is an adverse prognostic factor in MLL-rearranged infant acute lymphoblastic leukaemia

AU - Driessen, Emma M.C.

AU - Pinhanços, Sandra S.Mimoso

AU - Schneider, Pauline

AU - De Lorenzo, Paola

AU - Valsecchi, Maria G.

AU - Pieters, Rob

AU - Stam, Ronald W.

N1 - Funding Information: The authors thank the members and participating institutes of the INTERFANT-99 study for generously providing leukaemic samples. Members of the INTERFANT-99 study are as follows: M. Campbell (Programa Infantil Nacional de Drogas Atineoplasicas [PINDA]), M. Felice (Argentina), A. Ferster (Children's Leukaemia Group [CLCG]), I. Hann and A. Vora (UK Children's Cancer Study Group [UKCCSG]), L. Hovi (Nordic Society of Paediatric Haematology and Oncology [NOPHO]), G. Janka-Schaub (Cooperative Study Group for Treatment of ALL [COALL]), C.K. Li (Hong Kong), G. Mann (Berlin-Frankfurt-Munster Group-Austria [BFM-A]), T. LeBlanc (French ALL Group [FRALLE]), R. Pieters (Dutch Childhood Oncology Group [DCOG]), G. de Rossi and A. Biondi (Associazione Italiana Ematologia Oncologia Pediatrica [AIEOP]), J. Rubnitz (St Jude Children's Research Hospital [SJCRH]), M. Schrappe (Berlin–Frankfurt–Munster Group Germany [BFM-G]), L. Silverman (Dana-Farber Cancer Institute [DFCI]), J. Stary (Czech Paediatric Haematology [CPH]), R. Suppiah (Australian and New Zealand Children's Haematology/Oncology Group [ANZCHOG]), T. Szczepanski (Polish Paediatric Leukaemia and Lymphoma Study Group [PPLLSG]), and M. Valsecchi and P. de Lorenzo (Trial Operating Center [CORS]). Research support: this study was financially supported by research funding from KIKA (Kinderen Kankervrij) . Furthermore, RWS was financially supported by the Dutch Cancer Society (KWF Kankerbestrijding) .

PY - 2016/4/1

Y1 - 2016/4/1

UR - http://www.scopus.com/inward/record.url?scp=84958974309&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.12.031

DO - 10.1016/j.ejca.2015.12.031

M3 - Letter

C2 - 26901613

AN - SCOPUS:84958974309

SN - 0959-8049

VL - 57

SP - 87

EP - 90

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -